This article is more than 5 years old. Information may no longer be current.
Eylea prefilled syringe approval leads weekly ophthalmology headlines
Here are some of the recent top stories on Healio.com/OSN:
FDA approves Eylea prefilled syringe
The 2-mg, single-dose, sterilized prefilled Eylea (aflibercept) syringe, which requires fewer preparation steps compared with vials, is expected to be available by the end of the year. Read more.
BioTime rebrands as Lineage Cell Therapeutics
BioTime has changed its name to Lineage Cell Therapeutics to better reflect its commitment to becoming a leading cell therapy company. Read more.
Alembic’s generic dorzolamide hydrochloride solution approved
Indicated for the treatment of elevated IOP in ocular hypertension or open-angle glaucoma patients, it is therapeutically equivalent to Trusopt ophthalmic solution 2% (Merck). Read more.
Quality of sleep associated with glaucoma
Poor sleep parameters, including sleep duration, latency and daytime dysfunction, are associated with glaucoma, either as a risk factor or as a consequence. Read more.
Real-world rates of suspected endophthalmitis after injections similar to clinical trial rates
In a large retrospective review of real-world rates of endophthalmitis after intravitreal anti-VEGF and steroid injections, rates were low and similar to reported rates in clinical trials. Read more.